# OnCo record rucaparib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/rucaparib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "rucaparib" ;
  schema:name "Rucaparib"@en ;
  schema:description "Rucaparib is a DNA-repair inhibitor for selected BRCA-mutated ovarian and prostate cancers. Its prostate indication received regular US approval in December 2025."@en ;
  schema:url <https://onco.cc/drugs/rucaparib/> ;
  schema:dateModified "2026-10-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Rucaparib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q7376558> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Rucaparib>, <https://doi.org/10.1056/NEJMoa2214676>, <https://www.nice.org.uk/guidance/ta887>, <https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22RUBRACA%22&limit=1>, <https://www.govinfo.gov/content/pkg/FR-2024-03-26/pdf/2024-06299.pdf>, <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-rucaparib-metastatic-castration-resistant-prostate-cancer> ;
  onco:status "approved" ;
  onco:modality "Small-molecule PARP inhibitor" ;
  schema:alternateName "Rubraca" ;
  onco:approval "US 2016: BRCA-mutated advanced ovarian cancer after at least two chemotherapies; this treatment indication was withdrawn", "US 2018: Recurrent ovarian, fallopian-tube or primary-peritoneal maintenance after platinum response; current scope is germline or somatic BRCA-mutated", "US 2020: Historical accelerated BRCA-mutated mCRPC approval after ARPI and taxane; replaced by regular approval in 2025", "US 2025: Regular approval, germline or somatic BRCA-mutated mCRPC after androgen receptor-directed therapy" ;
  onco:acceleratedApproval "US 2016-12-19: Deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer treated with 2 or more chemotherapies 2", "US 2020-05-15: Treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy" ;
  onco:acceleratedApprovalConfirmed "US 2018-04-06: Deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer treated with 2 or more chemotherapies 2", "US 2025-12-17: Treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy" ;
  onco:related <https://onco.cc/biomarkers/brca-somatic/> ;
  onco:cancers <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/high-grade-serous-ovarian-cancer/>, <https://onco.cc/cancers/platinum-sensitive-ovarian-cancer/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/brca-palb2-pdac/> ;
  onco:technologies <https://onco.cc/technologies/parp-inhibitor/> ;
  onco:targets <https://onco.cc/targets/parp/>, <https://onco.cc/targets/brca/> ;
  onco:companies <https://onco.cc/companies/pharmaand/> ;
  onco:terms <https://onco.cc/terms/hrd/>, <https://onco.cc/terms/prostate-hrr-eligibility/> ;
  onco:trials <https://onco.cc/trials/athena-mono/>, <https://onco.cc/trials/nct03542175/>, <https://onco.cc/trials/nct01074970/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-kalra-bre09-146-rucaparib-npj-2021/>, <https://onco.cc/key-papers/paper-reiss-rucaparib-maintenance-brca-palb2-pancreatic-jco-2021/> .